For-Robin Therapeutics, (F-R), is an antibody immunotherapy company, founded in 2012 by Dr. Kate Rittenhouse-Olson. The company's primary mission is treating breast cancer patients. Their proprietary technology, the monoclonal antibody JAA-F11 and humanized variants of it, targets all breast cancer cell subtypes, including triple negative breast cancer, which currently has no targeted therapy. This technology is also anticipated to be applicable to colon, prostate, and bladder carcinoma patient populations. As of the last investment in May 2015, the company received a . For-Robin plans to bring its core humanized JAA-F11 technology as an adjunct therapy to patient populations as quickly, safely, and efficaciously as possible. The company is headquartered in the United States.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant - For | $2.00M | - | 04 May 2015 |
No recent news or press coverage available for For-Robin, Inc..
We care about your data, and we'd love to use cookies make your experience better.
